Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: Results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients

Journal of Clinical Oncology

Volumn 16, Issue 4, 1998, Pages 1470-1478

  Gamelin, E ^a   Boisdron Celle, M ^a   Delva, R ^a   Regimbeau, C ^a   Cailleux, P E ^a   Alleaume, C ^a   Maillet, M L ^a   Goudier, M J ^a   Sire, M ^a   Person Joly, M C ^a   Maigre, M ^a   Maillart, P ^a   Fety, R ^a   Burtin, P ^a   Lortholary, A ^a   Dumesnil, Y ^a   Picon, L ^a   Geslin, J ^a   Gesta, P ^a   Danquechin Dorval, E ^a   Larra, F ^a   Robert, J ^a   more..

^a CENTRE PAUL PAPIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME;

EID: 0031901763     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.4.1470     Document Type: Article

References (39)

1. Arbuck SG: Overview of clinical trials using 5-fluorouracil and leucovorin tor the treatment of colorectal cancer. Cancer 63:1036-1044, 1989
2. Bruckner HW, Motwani BT: Chemotherapy of advanced cancer of the colon and rectum. Semin Oncol 18:443-461, 1991
3. Poon MA, O'Connell MJ, Wieand HS: Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved efficacy in advanced colorectal cancer. J Clin Oncol 9:1967-1972, 1991
4. Diaz-Rubio E, Aranda E, Martin M, et al: Weekly high dose infusion of 5-fluorouracil in advanced colorectal cancer. Eur J Cancer 26:727-729, 1990
5. Hryniuk WM, Figueredo A, Goodyear M: Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 14:3-11, 1987
6. Ardalan B, Chua L, vTian E, et al: A phase II study of weekly 24 hour infusion with high dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 9:625-630, 1991
7. Spicer DV, Ardalan B, Daniels JR, et al: Reevaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokinetics. Cancer Res 48:459-461, 1988
8. Wils JA: High dose fluorouracil: A new perspective in the treatment of colorectal cancer? Semin Oncol 19:126-130, 1992 (suppl3)
9. Brohee D: 5-fluorouracil and folinic acid in the treatment of advanced colorectal cancer: An updated meta-analysis. Med Sci Res 22:383-384, 1994
10. Shah A, MacDonald W, Goldie J, et al: 5-FU infusion in advanced colorectal cancer: A comparison of three dose schedules. Cancer Treat Rep 69:739-742, 1985
11. Santini J, Milano G, Thyss A. et al: 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 59:287-290, 1989
12. Thyss A, Milano G, Renée N, et al: Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother Pharmacol 16:64-66, 1986
13. Milano G, Roman P, Khater P, et al: Dose versus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU. Int J Cancer 41:537-541, 1988
14. Fety R, Rolland F, Barberi-Heyob M, et al: Clinical randomized study of 5-FU monitoring versus standard dose in patients with head and neck cancer: Preliminary results. Anticancer Res 14: 2347-2352, 1994
15. Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, et al: Relationship between 5fluorouracil dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 77:441-451, 1996
16. Hillcoat BL, McCulloch PB, Figueredo AT, et al: Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. Br J Cancer 38:719-724, 1978
17. Seitz JF, Cano JP, Rigault JP, et al: Chimiothérapie des cancers digestifs étendus par le 5-fluorouracile: Relations entre la réponse clinique et la clairance plasmatique du médicament. Gastroenterol Clin Biol 7:374-380, 1983
18. Diasio RB, Harris BE: Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16:215-237, 1989
19. Etienne MC, Lagrange JL, Dassonville O, et al: Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12:2248-2253, 1994
20. Fleming R, Milano G, Thyss A, et al: Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52:2899-2902, 1992
21. Harris BE, Song R, Soong SJ, et al: Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50:197-201, 1990
22. Lu Z, Zhang R, Diasio RB: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53:5433-5438, 1993
23. Milano G, Etienne M C, Cassuto-Viguier E, et al: Influence of sex and age on fluorouracil clearance. J Clin Oncol 10:1171-1175, 1992
24. Naguib FNM, el Kouni M, Cha S: Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 45:5405-5412, 1985
25. Pinedo HM, Peters GFJ: Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 6:1653-1664, 1988
26. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
27. Moertel CG, Fleming TR, MacDonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352-358, 1990
28. Machover D, Goldschmidt E, Chollet P: Treatment of advanced colorectal and gastric adenocarcinoma with 5-fluorouracil and high dose folinic acid. J Clin Oncol 4:685-696, 1986
29. de Gramont A, Bosset JF, Milan C et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer. J Clin Oncol 15:808-815, 1997
30. Lokich JJ, Ahlgren JD, Gullo JJ, et al: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. J Clin Oncol 7:425-432, 1989
31. Seifert P, Baker LH, Reed ML, et al: Comparison of continuously infused 5-fluorouracil with bolus injection in the treatment of patients with colorectal carcinoma. Cancer 36:123-128, 1975
32. Tramp DL, Egorin MJ, Forrest A, et al: Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J Clin Oncol 9: 2027-2035, 1991
33. Van Groeningen CJ, Pinedo HM, Heddes J, et al: Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res 48:6956-6961, 1988
34. Yoshida T, Araki E, Ligo M, et al: Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonie cancer. Cancer Chemother Pharmacol 26:352-354, 1990
35. Beck A, Etienne MC, Cheradame S, et al: A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil. Eur J Cancer 30:1517-1522, 1994
36. Etienne MC, Cheradame S, Fischel JL et al: Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13:1663-1670, 1995
37. Erlichman C, Fine S, Elhakim T: Plasma pharmacokinetic of 5-FU given by continuous infusion with allopurinol. Cancer Treat Rep 70:903-904, 1986
38. Wagner JG, Gyves JW, Stetson PL, et al: Steady-state non linear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. Cancer Res 46: 1499-1506, 1986
39. McDermott BJ, Van den Berg HW, Murphy RF: Non linear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients. Cancer Chemother Pharmacol 9:173-178, 1982